South Africa’s hepatitis B birth-dose policy could avert more chronic infection with broader newborn coverage
South Africa’s current approach to hepatitis B prevention is selective, not universal. Babies born to mothers with confirmed hepatitis B are eligible for hepatitis B birth-dose vaccination in addition to peripartum antiviral prophylaxis, while newborns without known maternal infection do not routinely receive the birth dose. A mathematical modelling analysis published in The Lancet Global Health suggests that widening protection to all newborns would prevent more vertically acquired infection and could still be economically justified within the country’s elimination strategy.
The analysis matters because early-life transmission drives long-term disease burden. When hepatitis B is acquired at birth, the risk of progressing to chronic infection is far higher than after later exposure, and chronic infection creates the reservoir for cirrhosis, hepatocellular carcinoma, and premature death decades later. In that setting, even a single missed infant dose can alter a lifetime of risk.
Modelled protection reached beyond the current selective strategy
Investigators used a validated model of transmission, disease progression, and mortality to simulate South Africa’s ongoing hepatitis B epidemic. Three policy pathways were compared against a baseline of no hepatitis B birth-dose coverage: the current South African policy of selective peripartum antiviral prophylaxis plus selective birth-dose vaccination, a universal birth-dose-only approach, and the World Health Organization-endorsed strategy of selective peripartum antiviral prophylaxis plus universal birth-dose vaccination. Outcomes were projected over a 2025 to 100 time horizon, with costs reported in consumer price index-adjusted 2024 South African rand and outcomes discounted at 3% annually.
Across those scenarios, the selective current policy was the most efficient in one narrow sense: it required far fewer vaccinations per outcome averted. The number needed to vaccinate per vertically acquired chronic hepatitis B infection averted was six, with a 95% uncertainty interval of 3 to 15. By comparison, the universal birth-dose-only policy required 462 vaccinations per chronic infection averted, with an uncertainty interval of 223 to 1479. The combined selective prophylaxis plus universal birth-dose strategy landed between those two extremes, at 77 vaccinations per chronic infection averted, with an uncertainty interval of 38 to 240.
The numbers expose a tension that sits at the heart of hepatitis B prevention. Selective strategies can look efficient on paper because they concentrate resources in mothers already known to be infected, but they depend on prenatal identification, timely linkage to care, and perfect execution at birth. Universal newborn vaccination avoids those bottlenecks. In practice, a policy that immunizes every infant closes the gap left by missed maternal testing, late presentation, and unrecognized infection.
The most expensive pathway prevented the most disease
The combined strategy of selective peripartum antiviral prophylaxis plus universal birth-dose vaccination incurred the greatest programmatic costs, yet it also averted the largest disease burden and emerged as the most cost-effective option at a willingness-to-pay threshold of 0.5 times per-capita gross domestic product, calculated as ZAR 57,281. Within the modelling framework, broader newborn vaccination paid for itself through downstream prevention of chronic infection and its complications.
That result fits the biology of hepatitis B transmission. Antiviral prophylaxis during late pregnancy lowers maternal viral load and reduces the chance of perinatal transmission, while the birth dose gives the newborn immediate active immunization during the narrow window before virus exposure becomes established. Using both layers together addresses two different parts of the transmission chain: maternal infectivity and neonatal susceptibility.
The study also places South Africa’s 2023 selective birth-dose policy in a broader policy debate. With an estimated hepatitis B prevalence of 4.7% to 6.0% in 2022, the country is not dealing with an isolated infection problem; it is managing a substantial population-level reservoir. In that context, a universal birth-dose policy is not simply an added intervention. It is a structural safeguard against incomplete maternal screening and missed opportunities in the delivery setting.
Chronic infection prevention is the central clinical prize
Averted chronic hepatitis B infection is the endpoint that matters most here. Chronic infection is what drives long-term liver inflammation, fibrosis, cirrhosis, and liver cancer, and those complications carry high human and financial costs over decades. Preventing infection at birth avoids the need for later surveillance, antiviral treatment, and management of end-stage liver disease. It also reduces future transmission from infected children and adults, extending the effect beyond the index birth cohort.
One concise signal stands out from the modelling: the current selective policy is lean, but the combined universal strategy prevents more disease. The model did not present universal newborn vaccination as a replacement for antenatal care; it framed it as reinforcement. In a health system where maternal testing and peripartum prophylaxis will never be perfectly complete, a universal birth dose reduces the chance that a child slips through the cracks.
Elimination strategy now has a stronger economic case
The interpretation is direct. These findings support implementation of a universal hepatitis B birth-dose policy alongside South Africa’s existing viral transmission elimination efforts. The model suggests that the broader policy delivers the greatest health gain and remains cost-effective within the threshold used in the analysis.
Still, the policy decision will depend on implementation realities that the model cannot fully resolve: vaccine procurement, delivery at birth, maternal screening coverage, and the logistics of reaching infants who deliver outside well-resourced facilities. The model also assumes a long horizon, which is appropriate for a chronic viral disease, but it means the financial return unfolds slowly while the health gains accumulate over years and decades.
Even so, the clinical direction is difficult to ignore. When the goal is to stop hepatitis B before it becomes a lifelong infection, coverage at birth is a powerful lever. Universal newborn vaccination broadens that lever beyond the mothers already identified in pregnancy, and in South Africa’s setting, that broader reach appears to be the more cost-effective path to elimination.